GeneDx (NASDAQ:WGS) Posts Quarterly Earnings Results, Beats Estimates By $0.20 EPS

GeneDx (NASDAQ:WGS) posted its quarterly earnings data on Monday. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.20, FiscalAI reports. The firm had revenue of $114.44 million for the quarter, compared to analysts’ expectations of $111.01 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.

Here are the key takeaways from GeneDx’s conference call:

• Record testing volume and return to profitability: GeneDx processed 30,785 exome and genome tests in Q2, up 32% year over year, generated $114.4 million in revenue, and posted $0.4 million in adjusted net income. The company reaffirmed full-year revenue guidance of $475 million–$490 million and expects to remain profitable for 2026.
• Coverage expansion creates a potential reimbursement tailwind: Commercial genome coverage increased from 47% to 87% of covered lives, driven largely by Carelon, while 39 states now cover exome or genome testing through Medicaid. Management expects the revenue impact to begin emerging in Q4 2026 and become more significant in 2027 as coverage translates into claims payments.
• Revenue cycle management is the primary growth opportunity but remains early: The outpatient genome collection rate was approximately 32%, with exome rates described as comparable, versus management’s long-term target of roughly 70%. Payer-specific workflows, improved prior authorization and denial management, and technology investments are being implemented, but collection rates are expected to remain roughly flat in Q3.
• Demand is broadening beyond GeneDx’s core markets: The company maintained about 80% share among geneticists and reached roughly 50% among pediatric neurologists, while General Pediatrics and prenatal testing showed early growth. New sales representatives, corporate pediatric accounts, and the planned “one-minute” ordering tool are expected to support further adoption.
• Liquidity and operating efficiency improved: GeneDx completed its planned $25 million in annual cost reductions, expanded its debt facility by $50 million, and received a strategic equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million. Management also cited gross-margin improvement to 70%, additional AI-driven productivity opportunities, and a return to cash-flow generation expected in Q4.

GeneDx Price Performance

GeneDx stock traded up $2.75 during midday trading on Monday, reaching $67.86. 1,698,833 shares of the stock traded hands, compared to its average volume of 999,035. The stock has a market cap of $2.01 billion, a P/E ratio of -25.32 and a beta of 1.92. The stock’s fifty day moving average is $60.67 and its 200-day moving average is $69.59. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. GeneDx has a 12 month low of $32.21 and a 12 month high of $170.87.

Analysts Set New Price Targets

A number of equities analysts have weighed in on WGS shares. Guggenheim reiterated a “buy” rating and issued a $74.00 price target (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. BTIG Research cut their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. TD Cowen reissued a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Piper Sandler reissued an “overweight” rating and issued a $63.00 price target (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $87.43.

Insider Transactions at GeneDx

In other news, CFO Kevin Feeley sold 3,729 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total value of $226,611.33. Following the sale, the chief financial officer directly owned 39,954 shares in the company, valued at $2,428,004.58. The trade was a 8.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister purchased 46,273 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the acquisition, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. The trade was a 0.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. Corporate insiders own 25.17% of the company’s stock.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently modified their holdings of WGS. Royal Bank of Canada raised its holdings in GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of GeneDx by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after acquiring an additional 453 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new stake in GeneDx in the 2nd quarter worth about $249,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: GeneDx reported its second-quarter 2026 financial and operating results on August 3. The release is the primary near-term catalyst for the stock, although the supplied article details do not include revenue, earnings, cash-flow, or guidance figures needed to determine whether the results exceeded expectations. GeneDx Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Several investor-rights law firms publicized a securities class action against GeneDx and certain officers, alleging violations of federal securities laws for investors who acquired shares between April 16, 2025, and May 4, 2026. The announcements primarily remind investors of the August 3 deadline to seek lead-plaintiff status; the allegations have not been proven, but the litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. GeneDx Class Action Announcement Faruqi GeneDx Class Action Deadline

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.